Glucotrack Appoints Neuromodulation and Painful Diabetic Neuropathy Expert, Usman Latif, MD, MBA, to Clinical Advisory Team

Core Insights - Glucotrack, Inc. has appointed Dr. Usman Latif to its clinical advisory team to enhance its strategy for integrated glucose monitoring applications, particularly focusing on epidural glucose monitoring alongside its continuous blood glucose monitor (CBGM) [1][5]. Company Overview - Glucotrack, Inc. specializes in the design, development, and commercialization of innovative technologies for diabetes management, including a long-term implantable continuous blood glucose monitoring system [8][9]. Key Developments - The company has successfully completed a long-term preclinical study demonstrating the feasibility and safety of glucose monitoring in the epidural space, which builds on its existing glucose sensing capabilities [5]. - Dr. Latif's expertise in pain management and neuromodulation is expected to significantly contribute to the development of integrated disease and device management solutions for patients suffering from Painful Diabetic Neuropathy (PDN) [2][4]. Market Context - PDN affects approximately 20% of the over 38 million Americans with diabetes, translating to more than 7 million individuals, highlighting a significant market opportunity for integrated glucose monitoring solutions [4]. - Spinal Cord Stimulation (SCS) technology has been recognized as an effective treatment option for providing long-term pain relief to PDN patients, which aligns with Glucotrack's vision of integrating glucose monitoring into existing pain management therapies [4].